<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress/2.3.3" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>

<channel>
	<title>Blog TramadolPlus.net</title>
	<link>http://blog.tramadolplus.net</link>
	<description>tramadol plus blog</description>
	<pubDate>Mon, 25 Aug 2008 07:43:38 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.3.3</generator>
	<language>en</language>
			<item>
		<title>Mutant polycystin-2 induces proliferation in primary rat tubular epithelial cells in a STAT-1/p21-independent fashion accompanied instead by alterations in expression
 of p57KIP2 and Cdk2</title>
		<link>http://blog.tramadolplus.net/2008/08/25/mutant-polycystin-2-induces-proliferation-in-primary-rat-tubular-epithelial-cells-in-a-stat-1p21-independent-fashion-accompanied-instead-by-alterations-in-expression-of-p57kip2-and-cdk2/</link>
		<comments>http://blog.tramadolplus.net/2008/08/25/mutant-polycystin-2-induces-proliferation-in-primary-rat-tubular-epithelial-cells-in-a-stat-1p21-independent-fashion-accompanied-instead-by-alterations-in-expression-of-p57kip2-and-cdk2/#comments</comments>
		<pubDate>Mon, 25 Aug 2008 07:43:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/08/25/mutant-polycystin-2-induces-proliferation-in-primary-rat-tubular-epithelial-cells-in-a-stat-1p21-independent-fashion-accompanied-instead-by-alterations-in-expression-of-p57kip2-and-cdk2/</guid>
		<description><![CDATA[
Abstract (provisional)
Background
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by the formation of multiple fluid-filled cysts that destroy the kidney architecture resulting in end-stage renal failure. Mutations in genes PKD1 and PKD2 account for nearly all cases of ADPKD. Increased cell proliferation is one of the key features of the disease. Several studies indicated that [...]]]></description>
			<content:encoded><![CDATA[<p><center><a rel="nofollow,noindex" href="http://askaak.net/in.cgi?10&#038;group=top&#038;parameter=1"><img src="http://pictrash.com/banner/pharma/ba/top/1.gif"></a></center><br/><br />
<h4>Abstract (provisional)</h4>
<h4>Background</h4>
<p>Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by the formation of multiple fluid-filled cysts that destroy the kidney architecture resulting in end-stage renal failure. Mutations in genes PKD1 and PKD2 account for nearly all cases of ADPKD. Increased cell proliferation is one of the key features of the disease. Several studies indicated that polycystin-1 regulates cellular proliferation through various signaling pathways, but little is known about the role played by polycystin-2, the product of PKD2. Recently, it was reported that as with polycystin-1, polycystin-2 can act as a negative regulator of cell growth by modulating the levels of the cyclin-dependent kinase inhibitor, p21 and the activity of the cyclin-dependent kinase 2, Cdk2. </p>
<h4>Methods</h4>
<p>Here we utilized different kidney cell-lines expressing wild-type and mutant PKD2 as well as primary tubular epithelial cells isolated from a PKD transgenic rat to further explore the contribution of the p21/Cdk2 pathway in ADPKD proliferation. </p>
<h4>Results</h4>
<p>Surprisingly, over-expression of wild-type PKD2 in renal cell lines failed to inactivate Cdk2 and consequently had no effect on cell proliferation. On the other hand, expression of mutated PKD2 augmented proliferation only in the primary tubular epithelial cells of a rat model but this was independent of the STAT-1/p21 pathway. On the contrary, multiple approaches revealed unequivocally that expression of the cyclin-dependent kinase inhibitor, p57KIP2, is downregulated, while p21 remains unchanged. This p57 reduction is accompanied by an increase in Cdk2 levels. </p>
<h4>Conclusions</h4>
<p>Our results indicate the probable involvement of p57KIP2 on epithelial cell proliferation in ADPKD implicating a new mechanism for mutant polycystin-2 induced proliferation. Most importantly, contrary to previous studies, abnormal proliferation in cells expressing mutant polycystin-2 appears to be independent of STAT-1/p21. </p>
<p><br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/25/determinants-of-self-rated-health-and-mortality-in-russia-are-they-the-same/">Determinants of self rated health and mortality in Russia - are they the same ? </a>, <a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a>, <a href="http://blog.tramadolplus.net/2008/08/01/oxpentifylline-versus-placebo-in-the-treatment-of-erythropoietin-resistant-anaemia-a-randomized-controlled-trial/">Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial</a>, <a href="http://blog.tramadolplus.net/2008/07/28/nexmed-receives-fda-response-for-erectile-dysfunction-product/">NexMed Receives FDA Response For Erectile Dysfunction Product</a>, <a href="http://blog.tramadolplus.net/2008/07/29/practice-characteristics-and-prescribing-of-cardiovascular-drugs-in-areas-with-higher-risk-of-chd-in-scotland-cross-sectional-study/">Practice characteristics and prescribing of cardiovascular drugs in areas with higher risk of CHD in Scotland: cross-sectional study</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/08/25/mutant-polycystin-2-induces-proliferation-in-primary-rat-tubular-epithelial-cells-in-a-stat-1p21-independent-fashion-accompanied-instead-by-alterations-in-expression-of-p57kip2-and-cdk2/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Maternal mortality in South Africa in 2001:
from demographic census to epidemiological investigation</title>
		<link>http://blog.tramadolplus.net/2008/08/21/maternal-mortality-in-south-africa-in-2001from-demographic-census-to-epidemiological-investigation/</link>
		<comments>http://blog.tramadolplus.net/2008/08/21/maternal-mortality-in-south-africa-in-2001from-demographic-census-to-epidemiological-investigation/#comments</comments>
		<pubDate>Thu, 21 Aug 2008 16:36:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/08/21/maternal-mortality-in-south-africa-in-2001from-demographic-census-to-epidemiological-investigation/</guid>
		<description><![CDATA[
Abstract (provisional)

Background
Maternal mortality remains poorly researched in Africa, and is likely to worsen dramatically as a consequence of HIV/AIDS.
Methods
The 2001 census of South Africa included a question on deaths in the previous 12 months, and two questions on external causes and maternal mortality, defined as &#8220;pregnancy-related deaths&#8221;. A microdata sample from the census permits researchers [...]]]></description>
			<content:encoded><![CDATA[<p><center><a rel="nofollow,noindex" href="http://askaak.net/in.cgi?10&#038;group=top&#038;parameter=2"><img src="http://pictrash.com/banner/pharma/ba/top/2.gif"></a></center><br/><br />
<h4>Abstract (provisional)</h4>
</p>
<h4>Background</h4>
<p>Maternal mortality remains poorly researched in Africa, and is likely to worsen dramatically as a consequence of HIV/AIDS.</p>
<h4>Methods</h4>
<p>The 2001 census of South Africa included a question on deaths in the previous 12 months, and two questions on external causes and maternal mortality, defined as &#8220;pregnancy-related deaths&#8221;. A microdata sample from the census permits researchers to assess levels and differentials in maternal mortality, in a country severely affected by high death rates from HIV/AIDS and from external causes. </p>
<h4>Results</h4>
<p>After correcting for several minor biases, our estimate of the Maternal Mortality Ratio (MMR) in 2001 was 542 per 100,000 live births. This level is much higher than previous estimates dating from pre-HIV/AIDS times. This high level occurred despite a relatively low proportion of maternal deaths (6.4%) among deaths of women aged 15-49 years, and was due to the astonishingly high level of adult mortality, some 4.7 times higher than expected from mortality below age 15 or above age 50. The main reasons for these excessive levels were HIV/AIDS and external causes of deaths. Our regional estimates of MMR were found to be consistent with other findings in the Cape Town area, and with the Agincourt DSS. The differentials in MMR were considerable: 1 to 9.2 for population groups (race), 1 to 3.2 for provinces, and 1 to 2.4 for levels of education. Relationship with income and wealth were complex, with highest values for middle income and middle wealth index. The effect of urbanization was small, and reversed in a multivariate analysis. Higher risks in provinces were not necessarily associated with lower income, lower education or higher proportions of home delivery, but correlated primarily with the prevalence of HIV/AIDS. </p>
<h4>Conclusions</h4>
<p>Demographic census microdata offer the opportunity to conduct an epidemiologic analysis of maternal mortality. In the case of South Africa, the level of MMR increased dramatically over the past 10 years, most likely because of HIV/AIDS. Indirect causes of maternal deaths appear much more important than direct obstetric causes. The MMR appears no longer to be a reliable measure of the quality of obstetric care or a measure of safe motherhood. </p>
<p><br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a>, <a href="http://blog.tramadolplus.net/2008/08/13/causes-for-sexual-dysfunction-change-as-people-age-earlier-experiences-with-multiple-partners-and-stds-take-their-toll/">Causes For Sexual Dysfunction Change As People Age - Earlier Experiences With Multiple Partners And STDs Take Their Toll</a>, <a href="http://blog.tramadolplus.net/2008/08/01/oxpentifylline-versus-placebo-in-the-treatment-of-erythropoietin-resistant-anaemia-a-randomized-controlled-trial/">Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial</a>, <a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a>, <a href="http://blog.tramadolplus.net/2008/08/07/health-canada-advises-consumers-not-to-use-rize-2-the-occasion-capsules-or-any-unauthorized-erectile-dysfunction-products/">Health Canada Advises Consumers Not To Use Rize 2 The Occasion Capsules Or Any Unauthorized Erectile Dysfunction Products</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/08/21/maternal-mortality-in-south-africa-in-2001from-demographic-census-to-epidemiological-investigation/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Causes For Sexual Dysfunction Change As People Age - Earlier Experiences With Multiple Partners And STDs Take Their Toll</title>
		<link>http://blog.tramadolplus.net/2008/08/13/causes-for-sexual-dysfunction-change-as-people-age-earlier-experiences-with-multiple-partners-and-stds-take-their-toll/</link>
		<comments>http://blog.tramadolplus.net/2008/08/13/causes-for-sexual-dysfunction-change-as-people-age-earlier-experiences-with-multiple-partners-and-stds-take-their-toll/#comments</comments>
		<pubDate>Wed, 13 Aug 2008 11:39:55 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/08/13/causes-for-sexual-dysfunction-change-as-people-age-earlier-experiences-with-multiple-partners-and-stds-take-their-toll/</guid>
		<description><![CDATA[Sexual dysfunction is not an inevitable part of aging, but it is strongly related a number of factors, such as mental and physical health, demographics and lifetime experiences, many of which are interrelated, according to a new study by researchers at the University of Chicago.The study, funded by the National Institutes of Health, found that [...]]]></description>
			<content:encoded><![CDATA[<p><center><a rel="nofollow,noindex" href="http://askaak.net/in.cgi?10&#038;group=bottom&#038;parameter=1"><img src="http://pictrash.com/banner/pharma/ba/bottom/1.gif"></a></center><br/>Sexual dysfunction is not an inevitable part of aging, but it is strongly related a number of factors, such as mental and physical health, demographics and lifetime experiences, many of which are interrelated, according to a new study by researchers at the University of Chicago.The study, funded by the National Institutes of Health, found that a history of sexually transmitted disease also has an impact on sexual health later in life. People who had an STD are also more likely to have had sexual experiences over their lifetimes that included more risks and multiple sex partners.&#8221;Having had an STD roughly quadruples a woman&#8217;s odds of reporting sexual pain and triples her lubrication problems,&#8221; said Edward Laumann, the George Herbert Mead Distinguished Service Professor of Sociology at the University, and lead author of the paper, &#8220;Sexual Dysfunction Among Older Adults: Prevalence and Risk Factors from a Nationally Representative U.S. Probability Sample of Men and Women 57 to 85 Years of Age,&#8221; published in the current issue of the <i>Journal of Sexual Medicine</i>. Men are more than five times as likely to report sex as non-pleasurable if they have previously had an STD. Laumann was joined in writing the paper by University researcher Aniruddha Das, and Linda Waite, the Lucy Flower Professor in Sociology at the University.The study showed that women may be more likely than men to experience sexual dysfunction because of health issues. The most common problem for men is erectile dysfunction, a problem that increases with age. &#8220;The results point to a need for physicians who are treating older adults experiencing sexual problems to take into account their physical health and also consider their mental health and their satisfaction with their intimate relationship in making any assessment,&#8221; Laumann said. The study is based on interviews with a national sample of 1,550 women and 1,455 men, ages 57 to 85, who were part of the 2005-2006 National Social Life, Health and Aging Project, a nationally representative survey of community-dwelling older U.S. adults. The survey collected data on social life, sexuality, health, and a broad range of biological measures. The study is a companion to a 1999 study Laumann led that looked at sexual dysfunction among men and women, ages 18 to 59. That study found that physical health was a bigger predictor of sexual problems for men than it was for women. For that younger age group, having an STD did not increase the odds of experiencing sexual dysfunction. The new study found that among older women, a common factor correlated with sexual dysfunction was urinary tract syndrome, which was associated with decreased interest in sex, as were mental health issues such as anxiety.Among men, mental health issues and relationship problems contributed to a lack of interest in sex and the inability to achieve orgasm, while being treated for urinary tract syndrome was associated with trouble maintaining and achieving an erection.Daily alcohol consumption seems to improve a woman&#8217;s sexual health, increasing her interest and pleasure in sex. Among men, there was no reported impact of alcohol consumption.Demographic characteristics and cultural factors also are related to sexual performance, the study found. Hispanic women were twice as likely to report pain during intercourse. Among men, blacks were twice as likely to report a lack of interest in sex and more likely to report climaxing too early. The National Social Life, Health, and Aging Project is supported by several components of the National Institutes of Health, including the National Institute on Aging, the Office of Research on Women&#8217;s Health, the Office of AIDS Research and the Office of Behavioral and Social Sciences Research. The National Opinion Research Center, whose staff was responsible for the data collection, also supports the project.University of Chicago<br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/25/determinants-of-self-rated-health-and-mortality-in-russia-are-they-the-same/">Determinants of self rated health and mortality in Russia - are they the same ? </a>, <a href="http://blog.tramadolplus.net/2008/08/07/health-canada-advises-consumers-not-to-use-rize-2-the-occasion-capsules-or-any-unauthorized-erectile-dysfunction-products/">Health Canada Advises Consumers Not To Use Rize 2 The Occasion Capsules Or Any Unauthorized Erectile Dysfunction Products</a>, <a href="http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/">Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia</a>, <a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a>, <a href="http://blog.tramadolplus.net/2008/08/05/association-of-kidney-function-with-inflammatory-and-procoagulant-markers-in-a-diverse-cohort-a-cross-sectional-analysis-from-the-multi-ethnic-study-of-atherosclerosis-mesa/">Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA)</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/08/13/causes-for-sexual-dysfunction-change-as-people-age-earlier-experiences-with-multiple-partners-and-stds-take-their-toll/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Medical Management And Surgical Management Of Peyronie&#8217;s Disease</title>
		<link>http://blog.tramadolplus.net/2008/08/10/medical-management-and-surgical-management-of-peyronies-disease/</link>
		<comments>http://blog.tramadolplus.net/2008/08/10/medical-management-and-surgical-management-of-peyronies-disease/#comments</comments>
		<pubDate>Sun, 10 Aug 2008 08:12:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/08/10/medical-management-and-surgical-management-of-peyronies-disease/</guid>
		<description><![CDATA[UroToday.com Peyronie&#8217;s disease is a scarring phenomenon affecting the tunica albuginea of the penis. Scar tissue forms &#8220;plaques&#8221; that can result in pain with erection, penile deviation, penile shortening, indentation, and/or erectile dysfunction. It is associated with difficulty with sexual intercourse and as such it is associated with loss of self-esteem and depression on the [...]]]></description>
			<content:encoded><![CDATA[<p>UroToday.com Peyronie&#8217;s disease is a scarring phenomenon affecting the tunica albuginea of the penis. Scar tissue forms &#8220;plaques&#8221; that can result in pain with erection, penile deviation, penile shortening, indentation, and/or erectile dysfunction. It is associated with difficulty with sexual intercourse and as such it is associated with loss of self-esteem and depression on the part of the patient and often on the part of the patient&#8217;s partner. There are no approved medical therapies for the treatment of Peyronie&#8217;s disease. Surgical treatment of Peyronie&#8217;s disease must be highly individualized, and various surgeons all have their &#8220;best way&#8221; of dealing with the problem. Peyronie&#8217;s disease was described by Francois de la Peyronie in 1743. Fallopius in 1561 probably described the entity that bares Peyronie&#8217;s name. Peyronie&#8217;s disease is incurable, patients require reassurance, they may benefit from medical therapy, and fortunately few require surgery. As mentioned, the scar tissue impedes the expansion of the corpora cavernosa. Peyronie&#8217;s disease has been associated with some medications. Beta blockers have been implicated, however, subsequent studies have not verified that relationship, and if there is a relationship to beta blockers, it is probably via erectile dysfunction, and not cause and effect of the beta blocker itself. The association with phenytoin has never been founded and is probably not real. A very nice study by Lyles from the University of North Carolina has associated Peyronie&#8217;s disease with patients who have Padgett&#8217;s disease of the bone. Diabetes mellitus has been implicated, and it is probably again via erectile dysfunction. About 40% of patients with Peyronie&#8217;s disease will show evidence of Dupuytren&#8217;s disease, albeit many will be non-contractile. A lesser percentage will show evidence of Ledderhose&#8217;s disease, and a very small number will have tympanosclerosis. Peyronie&#8217;s disease is a disease of patients between 45 and 65 years with a mean onset of 53 years old. The asymptomatic prevalence has been estimated to be as high as 20-25%. The years of peak incidence of Peyronie&#8217;s disease as it turns out are also the years during which the body begins to age, tissues lose elasticity, and men note the onset of erectile dysfunction. The current theory with regards to the etiology of Peyronie&#8217;s disease involves trauma to the insertion of the septal fibers. The dorsum appears to be particularly vulnerable. To this date, there is no firm association to HLA subtypes, autoimmune disease, but Peyronie&#8217;s disease is certainly a disease of hyperactive wound healing. The scar tissue is composed of dense collagen with decreased elastin. Patients can demonstrate dystrophic calcification and in some cases cartilaginous metaplasia. TGFß1 has been implicated as a part of the process involving the etiology of Peyronie&#8217;s disease. Other gross factors are also expressed, those being platelet derived growth factors A and B. TGFb1 has been implicated with other soft tissue fibrosis. It is implicated in ED. TGFß1 increases the synthesis of fibroblasts; and in short, it causes increased connective tissue as it governs the scarring process. It inhibits collagenase, and because of the unique anatomy of the insertion of the septal fibers, may be involved in a process of self-induction. All agree that Peyronie&#8217;s disease is a disease of two phases, an active or immature phase and a mature or quiescent phase. What the practitioner does for Peyronie&#8217;s disease is in many cases phase specific. The physician seeing a patient with Peyronie&#8217;s disease cannot underestimate the psychological impact on the patient and on his partner. With regards to medical management, the place of vitamin E, potaba, Colchicine, Tamoxifen, Carnitine, Pentoxifylline, and PDE5 inhibitors will be discussed. Where there are pertinent randomized controlled trials, those will be reviewed. It is clear that rigorous well-designed controlled studies have in the past not been uniformly done. They are needed, and we are in an era where that deficiency is being addressed. Intralesional injection will be addressed as will the randomized controlled trials associated with that. The place of topical therapy will be addressed, along with innovative delivery mechanisms such as iontophersis and electromotive therapy. The literature will be reviewed with regards to lithotripsy, and the place of combined medical therapy likewise reviewed. A patient becomes a surgical candidate when he has stable and quiescent disease and that usually is a time that is greater than a year from onset of symptoms. The deformity should be stable for at least 3-6 months. The patient should be erectile pain free. These patients require detailed assessment of their erectile function, and it is imperative that a true informed consent be conducted with the patient. Surgical management options include the plication or corporo &#8230;<br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a>, <a href="http://blog.tramadolplus.net/2008/08/05/association-of-kidney-function-with-inflammatory-and-procoagulant-markers-in-a-diverse-cohort-a-cross-sectional-analysis-from-the-multi-ethnic-study-of-atherosclerosis-mesa/">Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA)</a>, <a href="http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/">Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia</a>, <a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a>, <a href="http://blog.tramadolplus.net/2008/08/07/health-canada-advises-consumers-not-to-use-rize-2-the-occasion-capsules-or-any-unauthorized-erectile-dysfunction-products/">Health Canada Advises Consumers Not To Use Rize 2 The Occasion Capsules Or Any Unauthorized Erectile Dysfunction Products</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/08/10/medical-management-and-surgical-management-of-peyronies-disease/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Health Canada Advises Consumers Not To Use Rize 2 The Occasion Capsules Or Any Unauthorized Erectile Dysfunction Products</title>
		<link>http://blog.tramadolplus.net/2008/08/07/health-canada-advises-consumers-not-to-use-rize-2-the-occasion-capsules-or-any-unauthorized-erectile-dysfunction-products/</link>
		<comments>http://blog.tramadolplus.net/2008/08/07/health-canada-advises-consumers-not-to-use-rize-2-the-occasion-capsules-or-any-unauthorized-erectile-dysfunction-products/#comments</comments>
		<pubDate>Thu, 07 Aug 2008 16:07:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/08/07/health-canada-advises-consumers-not-to-use-rize-2-the-occasion-capsules-or-any-unauthorized-erectile-dysfunction-products/</guid>
		<description><![CDATA[Health Canada is warning consumers not to use Rize 2 The Occasion capsules (Rize2), an unauthorized product promoted for the treatment of erectile dysfunction, because it may pose serious health risks. Rize 2 contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil which should only be used under the supervision of a health [...]]]></description>
			<content:encoded><![CDATA[<p>Health Canada is warning consumers not to use Rize 2 The Occasion capsules (Rize2), an unauthorized product promoted for the treatment of erectile dysfunction, because it may pose serious health risks. Rize 2 contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil which should only be used under the supervision of a health care professional. The product may pose serious health risks, especially for patients with pre-existing medical conditions such as heart problems, those who may be taking heart medications, or those who may be at risk for strokes. Use of sildenafil by patients with heart disease can result in serious cardiovascular side-effects such as sudden cardiac death, heart attack, stroke, low blood pressure, chest pain and abnormal heartbeat. Additionally, use of sildenafil may be associated with other side-effects including vision loss, seizures, sudden decrease or loss of hearing, dizziness, prolonged erections, headaches, flushing, nasal congestion, indigestion and abdominal pain. Sildenafil should not be used by individuals taking any type of nitrate drug (e.g., nitroglycerin) due to the risk of developing potentially life-threatening low blood pressure. The distributor, Cana International Distributing, is conducting a voluntary recall of all lots of Rize 2 that are available at retail outlets across Canada and over the Internet. Health Canada advises retailers to remove this product from their shelves, and consumers should return the product to the place of purchase. Canadians who have used Rize 2 and are concerned about their health should consult with a health care professional. Health Canada is taking steps to confirm that the product has been removed from the Canadian market. In addition to Rize 2, Health Canada advises consumers not to use any unauthorized erectile dysfunction products, and recommends that consumers talk to a health care professional about authorized treatments for erectile dysfunction. Health Canada Health Canada is also reminding consumers to be cautious regarding the purchase of health products over the Internet or from outside of Canada, as these products may not have been assessed to the same standards as products approved for sale on the Canadian market. Authorized health products will bear either an eight-digit Drug Identification Number (DIN), a Natural Product Number (NPN), or a Homeopathic Medicine Number (DIN-HM). This authorization indicates that the products have been assessed by Health Canada for safety, effectiveness and quality. To report a suspected adverse reaction to this health product, please contact the Canada Vigilance Program of Health Canada by one of the following methods: Telephone: 1-866-234-2345 Facsimile: 1-866-678-6789Canada Vigilance Program Marketed Health Products Directorate Ottawa, Ontario, AL 0701C K1A 0K9E-mail: CanadaVigilance@hc-sc.gc.caThe Canada Vigilance adverse reaction reporting form, including a version that can be completed and submitted online, is located in the MedEffect Canada area of the Health Canada Web site.<br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a>, <a href="http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/">Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia</a>, <a href="http://blog.tramadolplus.net/2008/07/28/nexmed-receives-fda-response-for-erectile-dysfunction-product/">NexMed Receives FDA Response For Erectile Dysfunction Product</a>, <a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a>, <a href="http://blog.tramadolplus.net/2008/08/05/association-of-kidney-function-with-inflammatory-and-procoagulant-markers-in-a-diverse-cohort-a-cross-sectional-analysis-from-the-multi-ethnic-study-of-atherosclerosis-mesa/">Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA)</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/08/07/health-canada-advises-consumers-not-to-use-rize-2-the-occasion-capsules-or-any-unauthorized-erectile-dysfunction-products/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA)</title>
		<link>http://blog.tramadolplus.net/2008/08/05/association-of-kidney-function-with-inflammatory-and-procoagulant-markers-in-a-diverse-cohort-a-cross-sectional-analysis-from-the-multi-ethnic-study-of-atherosclerosis-mesa/</link>
		<comments>http://blog.tramadolplus.net/2008/08/05/association-of-kidney-function-with-inflammatory-and-procoagulant-markers-in-a-diverse-cohort-a-cross-sectional-analysis-from-the-multi-ethnic-study-of-atherosclerosis-mesa/#comments</comments>
		<pubDate>Tue, 05 Aug 2008 18:48:45 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/08/05/association-of-kidney-function-with-inflammatory-and-procoagulant-markers-in-a-diverse-cohort-a-cross-sectional-analysis-from-the-multi-ethnic-study-of-atherosclerosis-mesa/</guid>
		<description><![CDATA[Abstract (provisional)
Background
Prior studies using creatinine-based estimated glomerular filtration rate (eGFR) have found limited associations between kidney function and markers of inflammation. Using eGFR and cystatin C, a novel marker of kidney function, the authors investigated the association of kidney function with multiple biomarkers in a diverse cohort.
Methods
The Multi-Ethnic Study of Atherosclerosis consists of 6,814 participants [...]]]></description>
			<content:encoded><![CDATA[<h4>Abstract (provisional)</h4>
<h4>Background</h4>
<p>Prior studies using creatinine-based estimated glomerular filtration rate (eGFR) have found limited associations between kidney function and markers of inflammation. Using eGFR and cystatin C, a novel marker of kidney function, the authors investigated the association of kidney function with multiple biomarkers in a diverse cohort.</p>
<h4>Methods</h4>
<p>The Multi-Ethnic Study of Atherosclerosis consists of 6,814 participants of white, African-American, Hispanic, and Chinese descent, enrolled from 2000-2002 from six U.S. communities. Measurements at the enrollment visit included serum creatinine, cystatin C, and six inflammatory and procoagulant biomarkers. Creatinine-based eGFR was estimated using the four-variable Modification of Diet in Renal Disease equation, and chronic kidney disease was defined by an eGFR &lt; 60 mL/min/1.73m2.</p>
<h4>Results</h4>
<p>Adjusted partial correlations between cystatin C and all biomarkers were statistically significant: C-reactive protein (r=0.08), interleukin-6 (r=0.16), tumor necrosis factor-alpha soluble receptor 1 (TNF-alphaR1; r=0.75), intercellular adhesion molecule-1 (r=0.21), fibrinogen (r=0.14), and factor VIII (r=0.11; two-sided p&lt;0.01 for all). In participants without chronic kidney disease, higher creatinine-based eGFR was associated only with higher TNF-alphaR1 levels. </p>
<h4>Conclusions</h4>
<p>In a cohort characterized by ethnic diversity, cystatin C was directly associated with multiple procoagulant and inflammatory markers. Creatinine-based eGFR had similar associations with these biomarkers among subjects with chronic kidney disease.</p>
<p><br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a>, <a href="http://blog.tramadolplus.net/2008/08/01/oxpentifylline-versus-placebo-in-the-treatment-of-erythropoietin-resistant-anaemia-a-randomized-controlled-trial/">Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial</a>, <a href="http://blog.tramadolplus.net/2008/07/29/practice-characteristics-and-prescribing-of-cardiovascular-drugs-in-areas-with-higher-risk-of-chd-in-scotland-cross-sectional-study/">Practice characteristics and prescribing of cardiovascular drugs in areas with higher risk of CHD in Scotland: cross-sectional study</a>, <a href="http://blog.tramadolplus.net/2008/07/28/nexmed-receives-fda-response-for-erectile-dysfunction-product/">NexMed Receives FDA Response For Erectile Dysfunction Product</a>, <a href="http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/">Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/08/05/association-of-kidney-function-with-inflammatory-and-procoagulant-markers-in-a-diverse-cohort-a-cross-sectional-analysis-from-the-multi-ethnic-study-of-atherosclerosis-mesa/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial</title>
		<link>http://blog.tramadolplus.net/2008/08/01/oxpentifylline-versus-placebo-in-the-treatment-of-erythropoietin-resistant-anaemia-a-randomized-controlled-trial/</link>
		<comments>http://blog.tramadolplus.net/2008/08/01/oxpentifylline-versus-placebo-in-the-treatment-of-erythropoietin-resistant-anaemia-a-randomized-controlled-trial/#comments</comments>
		<pubDate>Fri, 01 Aug 2008 07:30:32 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/08/01/oxpentifylline-versus-placebo-in-the-treatment-of-erythropoietin-resistant-anaemia-a-randomized-controlled-trial/</guid>
		<description><![CDATA[Abstract (provisional)
Background
The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients.
Methods
Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including dialysis patients) with significant anaemia (haemoglobin less than or equal to 110 g/L) for at least 3 months for [...]]]></description>
			<content:encoded><![CDATA[<h4>Abstract (provisional)</h4>
<h4>Background</h4>
<p>The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients.</p>
<h4>Methods</h4>
<p>Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including dialysis patients) with significant anaemia (haemoglobin less than or equal to 110 g/L) for at least 3 months for which there is no clear identifiable cause and that is unresponsive to large doses of either erythropoietin (greater than or equal to 200 IU/kg/week) or darbepoetin (greater than or equal to 1 microgram/kg/week). Patients will be randomized 1:1 to receive either placebo (1 tablet daily) or oxpentifylline (400 mg daily) per os for a period of 4 months. During this 4 month study period, haemoglobin measurements will be performed monthly. The primary outcome measure will be the difference in haemoglobin level between the 2 groups at the end of the 4 month study period, adjusted for baseline values. Secondary outcome measures will include erythropoiesis stimulating agent dosage, Key&#8217;s index (erythropoiesis stimulating agent dosage divided by haemoglobin concentration), and blood transfusion requirement.</p>
<h4>Discussion</h4>
<p>This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in chronic kidney disease. Trial Registration: Australian Clinical Trials Registry Number ACTRN12608000199314. </p>
<p><br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a>, <a href="http://blog.tramadolplus.net/2008/07/28/nexmed-receives-fda-response-for-erectile-dysfunction-product/">NexMed Receives FDA Response For Erectile Dysfunction Product</a>, <a href="http://blog.tramadolplus.net/2008/07/25/determinants-of-self-rated-health-and-mortality-in-russia-are-they-the-same/">Determinants of self rated health and mortality in Russia - are they the same ? </a>, <a href="http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/">Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia</a>, <a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/08/01/oxpentifylline-versus-placebo-in-the-treatment-of-erythropoietin-resistant-anaemia-a-randomized-controlled-trial/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Practice characteristics and prescribing of cardiovascular drugs in areas with higher risk of CHD in Scotland: cross-sectional study</title>
		<link>http://blog.tramadolplus.net/2008/07/29/practice-characteristics-and-prescribing-of-cardiovascular-drugs-in-areas-with-higher-risk-of-chd-in-scotland-cross-sectional-study/</link>
		<comments>http://blog.tramadolplus.net/2008/07/29/practice-characteristics-and-prescribing-of-cardiovascular-drugs-in-areas-with-higher-risk-of-chd-in-scotland-cross-sectional-study/#comments</comments>
		<pubDate>Tue, 29 Jul 2008 11:40:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/07/29/practice-characteristics-and-prescribing-of-cardiovascular-drugs-in-areas-with-higher-risk-of-chd-in-scotland-cross-sectional-study/</guid>
		<description><![CDATA[Abstract
Background
We examine whether practices in areas with higher risks of CHD prescribe different levels of cardiovascular drugs and describe how they differ in GP and practice characteristics.
Methods
Propensity score matching was used to identify two groups of practices in Scotland. The cases were in areas with 5% or more of the population in South Asian ethnic [...]]]></description>
			<content:encoded><![CDATA[<h4>Abstract</h4>
<h4>Background</h4>
<p>We examine whether practices in areas with higher risks of CHD prescribe different levels of cardiovascular drugs and describe how they differ in GP and practice characteristics.</p>
<h4>Methods</h4>
<p>Propensity score matching was used to identify two groups of practices in Scotland. The cases were in areas with 5% or more of the population in South Asian ethnic groups. The controls were in areas with less than 1% of the population in South Asian ethnic groups and were matched for other population characteristics.</p>
<h4>Results</h4>
<p>The 39 case practices have lower prescribing rates than the matched controls for all heart disease drugs Significant different are found for six drugs (statins, ace Inhibitors, clopidogrel, thiazides, warfarin and digoxin. The differences range from 12.8% less for amlodipine to 43.9% for clopidogrel. The case practices also have lower prescribing costs than the unmatched group with the exception of ace inhibitors and aspirin. The highest prescribing costs for all drugs are found in the matched control group. The case practices are smaller than the controls, and have fewer GPs per 1,000 patients. Case practices have fewer quality markers and receive less in total resources, but have higher sums reimbursed to cover their employed staff costs.</p>
<h4>Conclusion</h4>
<p>Patients with higher risk of CHD tend to live in areas served by practices with lower prescribing rates and poorer structural characteristics. The scale of the differences in prescribing suggests that health care system factors rather than individual treatment decisions cause inequity in care. Identifying whether South Asian <em>individuals </em>are less likely to receive heart disease drugs than non South Asians requires individual-level prescribing data, which is currently not available in the UK.</p>
<h4>Background</h4>
<p>In 2003 CHD was second only to cancer as the major cause of mortality in Scotland. [1] Although CHD mortality has fallen in recent years death rates from CHD are amongst the highest in the world and the second highest in Western Europe. [2] There is a strong correlation between increasing incidence and mortality from CHD and deprivation. CHD is also the major cause of morbidity and mortality in the South Asian population in the United Kingdom. [3] South Asians have been found to be at increased risk compared to the rest of the population of England and Wales [4] by at least 40 percent. [5-7] Though Scotland has one of the worst incidences of heart disease in Europe [8] only one of the 19 studies identified in Bhopal&#8217;s review was based in Scotland. [4,9]</p>
<p>The concept of equity is a central objective of most health care systems in the developed world. While governments from across the political spectrum, both in the UK and internationally, have attempted to tackle perceived inequities in health care the concept of equity remains somewhat elusive. [10,11] A theoretical framework has been set out which examines equity through three domains: equal access to health care for people in equal need; equal treatment for people in equal need; and equal outcomes for people in equal need. [11] This simple framework has been used as a basis to examine the equity of GP prescribing rates for statins and five major CHD drug groups focused around the equal treatment in equal need domain. [12,13] These papers are amongst a growing body of work in the UK, which have focused on equity of prescribing. However, these studies have largely been confined to England and Wales. The purpose of this paper is to explore the equity of prescribing for a range of heart disease drugs in Scotland. Having established prescribing differences, the analysis then considers structural differences in GP and practice provision. Using a matching technique, we use examine the notion of equal treatment for people in equal need and how this relates to differences in equal access to health care.</p>
<p>Many patients do not receive the appropriate treatment for CHD. Research has found that prescribing rates of statins and lipid lowering drugs were negatively correlated with deprivation. [9,14] The Acheson report highlighted the need for studies of ethnic inequalities. [15] Several studies have highlighted ethnic variations in access to and provision of hospital interventions. [16,17] Although a more recent study found no evidence that South Asian ethnicity was associ</p>
<p><br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/">Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia</a>, <a href="http://blog.tramadolplus.net/2008/07/25/determinants-of-self-rated-health-and-mortality-in-russia-are-they-the-same/">Determinants of self rated health and mortality in Russia - are they the same ? </a>, <a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a>, <a href="http://blog.tramadolplus.net/2008/07/28/nexmed-receives-fda-response-for-erectile-dysfunction-product/">NexMed Receives FDA Response For Erectile Dysfunction Product</a>, <a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/07/29/practice-characteristics-and-prescribing-of-cardiovascular-drugs-in-areas-with-higher-risk-of-chd-in-scotland-cross-sectional-study/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia</title>
		<link>http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/</link>
		<comments>http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/#comments</comments>
		<pubDate>Tue, 29 Jul 2008 09:55:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/</guid>
		<description><![CDATA[Abstract
User fees were introduced in public health facilities in Cambodia in 1997 in order to inject funds into the health system to enhance the quality of services. Because of inadequate health insurance, a social safety net scheme was introduced to ensure that all people were able to attend the health facilities. However, continuing high rates [...]]]></description>
			<content:encoded><![CDATA[<h4>Abstract</h4>
<p>User fees were introduced in public health facilities in Cambodia in 1997 in order to inject funds into the health system to enhance the quality of services. Because of inadequate health insurance, a social safety net scheme was introduced to ensure that all people were able to attend the health facilities. However, continuing high rates of hospitalization and mortality from dengue fever among infants and children reflect the difficulties that women continue to face in finding sufficient cash in cases of medical emergency, resulting in delays in diagnosis and treatment. In this article, drawing on in-depth interviews conducted with mothers of children infected with dengue in eastern Cambodia, we illustrate the profound economic consequences for households when a child is ill. The direct costs for health care and medical services, and added indirect costs, deterred poor women from presenting with sick children. Those who eventually sought care often had to finance health spending through out-of-pocket payments and loans, or sold property, goods or labour to meet the costs. Costs were often catastrophic, exacerbating the extreme poverty of those least able to afford it.</p>
<h4>Background</h4>
<p>Resource-poor countries have long struggled to control infectious disease, reduce mortality and severe morbidity, and improve childhood survival rates with inadequate resources that are echoed in delayed diagnosis and poor service delivery at local levels. From the 1980s, various financing systems have been introduced to supplement government budgetary allocations, loans and bilateral aid, to deter the unnecessary use of health services, and from 1988, to improve access to and quality of services. The Bamako Initiative in particular emphasised the introduction of user fees, specifically to supplement the budgets of local health facilities, meeting salary and supply shortfalls, and so improve access and quality.</p>
<p>In an review published a decade ago, still apposite, Gilson notes the lack of attention to the ability of poor households to pay fees, and the effects of user fees on health seeking and treatment [1]. Subsequent studies in low and middle-income countries on the relationship between user fees and the utilization of public health services support claims that direct costs discourage presentation by poor people [2-5]. In Ghana, user fees have been shown to discourage presentation for antenatal and midwifery care, and consequently contribute to continued high maternal and neonatal mortality [6]. In Tanzania, despite general willingness to pay when quality of care at lower-level health facilities was improved, the very poor, women and elderly were negatively affected [7]; in Niger, user fees also resulted in declining patients&#8217; attendance and variable cost recovery [8]. The current view therefore is that minimally, there need to be effective safety nets for poor and vulnerable households, with alternative approaches to user fees such as micro-health insurance and/or exemptions and waivers from cost sharing [7,9,10].</p>
<p>These studies, like those cited by Gilson [1,11], have largely been conducted in Africa. Yet despite the local impact of the Bamako Initiative (1988), health financing reforms to supplement government funds have been introduced far more extensively. One study in Laos produced similar results to the African studies, drawing attention to the negative impact of user fees on the very poor [12], but relatively little research has been conducted in Asia on user fees and health seeking behaviour. This is particularly important when early diagnosis and treatment is critical for individual outcomes and where prompt medical care is a cornerstone of control. This is the case for various infections, including acute respiratory infection, tuberculosis, malaria, and dengue fever, which predominate in resource-poor settings.</p>
<p>Appropriate funding mechanisms are necessary to ensure equitable access to health care. The costs of health care to consumers, and the sources from which money is derived to pay for health care, are therefore important from a policy perspective, because the health care system in Cambodia is heavily based on fees. In Cambodia, user fees were introduced in 1997 as a component of a broader suite of health care reforms introduced to generate cash to supplement the basic low salaries of health staff, so to motivate staff and discourage them from seeking unofficial payments from patients or undertaking extra jobs during official working time. Cash generated from user fees was also expected to contribute to the operational costs of health facilities, so improving the quality of health care. To ensure that the reforms would not prevent poor people from using government health facilities, the Ministry of Health</p>
<p><br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/">13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</a>, <a href="http://blog.tramadolplus.net/2008/07/25/determinants-of-self-rated-health-and-mortality-in-russia-are-they-the-same/">Determinants of self rated health and mortality in Russia - are they the same ? </a>, <a href="http://blog.tramadolplus.net/2008/07/28/nexmed-receives-fda-response-for-erectile-dysfunction-product/">NexMed Receives FDA Response For Erectile Dysfunction Product</a>, <a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/07/29/poverty-user-fees-and-ability-to-pay-for-health-care-for-children-with-suspected-dengue-in-rural-cambodia/feed/</wfw:commentRss>
		</item>
		<item>
		<title>13,915 reasons for equity in sexual offences legislation: a national school-based survey in South Africa</title>
		<link>http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/</link>
		<comments>http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/#comments</comments>
		<pubDate>Tue, 29 Jul 2008 09:50:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/</guid>
		<description><![CDATA[Abstract (provisional)

Objective
Prior to 2007, forced sex with male children in South Africa did not count as rape but as &#8220;indecent assault&#8221;, a much less serious offence. This study sought to document prevalence of male sexual violence among school-going youth.
Design
A facilitated self-administered questionnaire in nine of the 11 official languages in a stratified (province/metro/urban/ rural) last [...]]]></description>
			<content:encoded><![CDATA[<h4>Abstract (provisional)</h4>
</p>
<h4>Objective</h4>
<p>Prior to 2007, forced sex with male children in South Africa did not count as rape but as &#8220;indecent assault&#8221;, a much less serious offence. This study sought to document prevalence of male sexual violence among school-going youth.</p>
<h4>Design</h4>
<p>A facilitated self-administered questionnaire in nine of the 11 official languages in a stratified (province/metro/urban/ rural) last stage random national sample. Setting: Teams visited 5162 classes in 1191 schools, in October and November 2002. Participants: A total of 269,705 learners aged 10-19 years in grades 6-11. Of these, 126,696 were male. Main outcome measures: Schoolchildren answered questions about exposure in the last year to insults, beating, unwanted touching and forced sex. They indicated the sex of the perpetrator, and whether this was a family member, a fellow schoolchild, a teacher or another adult. Respondents also gave the age when they first suffered forced sex and when they first had consensual sex.</p>
<h4>Results</h4>
<p>Some 9% (weighted value based on 13915/127097) of male respondents aged 11-19 years reported forced sex in the last year. Of those aged 18 years at the time of the survey, 44% (weighted value of 5385/11450) said they had been forced to have sex in their lives and 50% reported consensual sex. Perpetrators were most frequently an adult not from their own family, followed closely in frequency by other schoolchildren. Some 32% said the perpetrator was male, 41% said she was female and 27% said they had been forced to have sex by both male and female perpetrators. Male abuse of schoolboys was more common in rural areas while female perpetration was more an urban phenomenon.</p>
<h4>Conclusions</h4>
<p>This study uncovers endemic sexual abuse of male children that was suspected but hitherto only poorly documented. Legal recognition of the criminality of rape of male children is a first step. The next steps include serious investment in supporting male victims of abuse, and in prevention of all childhood sexual abuse.</p>
<p><br/><b>Related posts: </b><a href="http://blog.tramadolplus.net/2008/07/25/determinants-of-self-rated-health-and-mortality-in-russia-are-they-the-same/">Determinants of self rated health and mortality in Russia - are they the same ? </a>, <a href="http://blog.tramadolplus.net/2008/07/27/study-confirms-that-levitra-on-demand-is-effective-in-patients-with-ed-after-nerve-sparing-prostatectomy/">Study Confirms That Levitra&reg; On Demand Is Effective In Patients With ED After Nerve-sparing Prostatectomy</a>, <a href="http://blog.tramadolplus.net/2008/07/28/nexmed-receives-fda-response-for-erectile-dysfunction-product/">NexMed Receives FDA Response For Erectile Dysfunction Product</a><img src="http://dev.holydns.com/pharmastats.php?n=25426" style="border: 0; margin: 0; padding: 0; width: 1px; height: 1px;"></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.tramadolplus.net/2008/07/29/13915-reasons-for-equity-in-sexual-offences-legislation-a-national-school-based-survey-in-south-africa/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
var pageTracker = _gat._getTracker("UA-2839331-8");
pageTracker._initData();
pageTracker._trackPageview();
</script>

